Acorda Therapeutics said the USPTO Patent Trials and Appeal Board (PTAB) upheld all four patents challenged via the inter partes review process.
The patents apply to AMPYRA (dalfampridine) extended release tablets, 10 mg.
These patents are set to expire in 2025, 2025, 2026 and 2027 respectively.
“The court decision reflects the merits of the case we presented and the validity and strength of our intellectual property for AMPYRA,” said Acorda CEO Ron Cohen.
“Medical innovation depends on the recognition of valid intellectual property claims.
“Our in-house legal team and external counsel presented a compelling case, and will continue to defend the validity of our intellectual property rights for AMPYRA.”
Acorda was advised by Gerald Flattmann, Naveen Modi, Thomas Phalen, Michael Stamiello, Daniel Zeilberger and Lucas Kressel of Paul Hastings LLP.
Acorda said these four patents, as well as one other that also pertains to AMPYRA, have also been challenged in the US District Court for the District of Delaware.
The court has completed the trial of the case, but not yet issued its decision, Acorda said.